Paper25904367
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Sterling TR and 9 others. Clin Infect Dis, 2015. Cited by 86 papers, by iCite.
Cite this record
ConductScience Library. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Papers, record 25904367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25904367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
- PubMed
- Publication types
- Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Isoniazid | Major topic |
| Latent Tuberculosis | Major topic |
| Respiratory Tract Diseases | Major topic |
| Rifampin | Major topic |
| Adolescent | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 AI094189 | NIAID NIH HHS | United States | P30AI094189 | PubMed and NIH |
Source NIH RePORTER
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00023452 | Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT01582711 | Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT | Background | ClinicalTrials.gov | |
| NCT02980016 | Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals | Background | ClinicalTrials.gov | |
| NCT03783728 | Video Based Directly Observed Therapy for Latent TB | Results | ClinicalTrials.gov |
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2781610 | Severe 'flu'-like symptoms due to isoniazid--a report of three cases. | Tubercle | 1989 | https://conductscience.org/library/papers/2781610 | PubMed |
| 2 | 637437 | Isoniazid and reaction to cheese. | Ann Intern Med | 1978 | https://conductscience.org/library/papers/637437 | PubMed |
| 3 | 7249508 | A method for estimating the probability of adverse drug reactions. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/7249508 | PubMed |
| 4 | 578277 | Spiking fever from isoniazid simulating a septic process. | JAMA | 1977 | https://conductscience.org/library/papers/578277 | PubMed |
| 5 | 4620295 | Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects. | Tubercle | 1974 | https://conductscience.org/library/papers/4620295 | PubMed |
| 6 | 17448577 | Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. | Vaccine | 2007 | https://conductscience.org/library/papers/17448577 | PubMed |
| 7 | 4544603 | Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin-dependent antibodies. | Scand J Respir Dis Suppl | 1973 | https://conductscience.org/library/papers/4544603 | PubMed |
| 8 | 4259217 | Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. | Br Med J | 1972 | https://conductscience.org/library/papers/4259217 | PubMed |
| 9 | 4468024 | Systemic reactions to intermittent rifampicin. | Bull Int Union Tuberc | 1974 | https://conductscience.org/library/papers/4468024 | PubMed |
| 10 | 23592889 | Testing for drug hypersensitivity syndromes. | Clin Biochem Rev | 2013 | https://conductscience.org/library/papers/23592889 | PubMed |
| 11 | 3204279 | 'Flu' syndrome on once monthly rifampicin. | Indian J Lepr | 1988 | https://conductscience.org/library/papers/3204279 | PubMed |
| 12 | 23661919 | Isoniazid-induced flu-like syndrome: A rare side effect. | Lung India | 2013 | https://conductscience.org/library/papers/23661919 | PubMed |
| 13 | 12241657 | Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. | Lancet | 2002 | https://conductscience.org/library/papers/12241657 | PubMed |
| 14 | 6614636 | Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. | Am Rev Respir Dis | 1983 | https://conductscience.org/library/papers/6614636 | PubMed |
| 15 | 25337749 | High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25337749 | PubMed |
| 16 | 3784760 | A possible 'flu' syndrome on once-monthly rifampicin. | Lepr Rev | 1986 | https://conductscience.org/library/papers/3784760 | PubMed |
| 17 | 1096388 | A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland. | Tubercle | 1975 | https://conductscience.org/library/papers/1096388 | PubMed |
| 18 | 766339 | The influence of age and sex on the incidence of the 'flu' syndrome and rifampicin-dependent antibodies in patients on intermittent rifampicin for tuberculosis. | Tubercle | 1975 | https://conductscience.org/library/papers/766339 | PubMed |
| 19 | 7730725 | "Flu" syndrome due to rifampin; experience with four cases. | Int J Lepr Other Mycobact Dis | 1995 | https://conductscience.org/library/papers/7730725 | PubMed |
| 20 | 1308530 | Rifampicin induced flu-syndrome and toxic psychosis. | Indian J Lepr | 1992 | https://conductscience.org/library/papers/1308530 | PubMed |
Cited by53
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42237122 | Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42237122 | PubMed |
| 42136397 | Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial. | Clin Infect Dis | 2026 | https://conductscience.org/library/papers/42136397 | PubMed |
| 41333648 | A Case of Evolving Hepatotoxicity Following Systemic Drug Reaction to Isoniazid-Rifapentine (3HP). | Case Reports Hepatol | 2025 | https://conductscience.org/library/papers/41333648 | PubMed |
| 40326358 | Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). | Emerg Microbes Infect | 2025 | https://conductscience.org/library/papers/40326358 | PubMed |
| 40262275 | Prevalence and treatment outcomes of latent tuberculosis infection among older patients with chronic obstructive pulmonary disease in an area with intermediate tuberculosis burden. | Emerg Microbes Infect | 2025 | https://conductscience.org/library/papers/40262275 | PubMed |
| 39957776 | The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. | Lancet Reg Health Southeast Asia | 2024 | https://conductscience.org/library/papers/39957776 | PubMed |
| 39887565 | Tuberculosis: An Update for the Clinician. | Respirology | 2025 | https://conductscience.org/library/papers/39887565 | PubMed |
| 39733063 | Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review. | Drugs | 2025 | https://conductscience.org/library/papers/39733063 | PubMed |
| 39582503 | Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda. | Open Forum Infect Dis | 2024 | https://conductscience.org/library/papers/39582503 | PubMed |
| 39374926 | Diagnosis and Treatment of Latent Tuberculosis Infection in Adults in South Korea. | Tuberc Respir Dis (Seoul) | 2025 | https://conductscience.org/library/papers/39374926 | PubMed |
| 39301134 | Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV. | IJTLD Open | 2024 | https://conductscience.org/library/papers/39301134 | PubMed |
| 38640958 | Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection. | J Infect Dis | 2024 | https://conductscience.org/library/papers/38640958 | PubMed |
| 37931950 | Syndrome pseudogrippal avec choc induit par la rifampicine chez une patiente atteinte d’infection tuberculeuse. | CMAJ | 2023 | https://conductscience.org/library/papers/37931950 | PubMed |
| 37918510 | Tuberculosis prevention: current strategies and future directions. | Clin Microbiol Infect | 2024 | https://conductscience.org/library/papers/37918510 | PubMed |
| 37855280 | An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions. | Med Chem | 2024 | https://conductscience.org/library/papers/37855280 | PubMed |
| 37669793 | Rifampin-induced flu-like syndrome with shock in a patient with tuberculosis infection. | CMAJ | 2023 | https://conductscience.org/library/papers/37669793 | PubMed |
| 37339341 | Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study. | J Int AIDS Soc | 2023 | https://conductscience.org/library/papers/37339341 | PubMed |
| 37143101 | Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials. | Arch Public Health | 2023 | https://conductscience.org/library/papers/37143101 | PubMed |
| 36966788 | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. | Lancet Respir Med | 2023 | https://conductscience.org/library/papers/36966788 | PubMed |
| 36815322 | Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/36815322 | PubMed |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| PYRIDOXINE | CHEMBL1364 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1364 | ChEMBL |
| RIFAPENTINE | CHEMBL1660 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1660 | ChEMBL |
| ISONIAZID | CHEMBL64 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL64 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25904367
GET https://conductscience.org/api/papers/v1/25904367/references?page=2